Marla Dubinsky, MD

Icahn School of Medicine
Mount Sinai, NY

Presentation(s):

• 38 - 52-Week Risankizumab Subcutaneous Maintenance Dosing Is Efficacious and Well Tolerated in Patients With Moderate to Severe Crohn’s Disease Who Had Delayed Response to 12-Weeks IV Risankizumab Induction

  Tuesday, October 25, 2022
  2:25 PM – 2:35 PM ET